Group 1 - Hualan Co., Ltd. announced that its wholly-owned subsidiary, Lingqing Zhizhi, has signed a capital increase agreement with several companies, including Shenzhen Jingtai and Kema Biotechnology [1] - Lingqing Zhizhi plans to invest RMB 20 million to acquire a 9.53% stake in Kema Biotechnology after the capital increase, which will increase Kema's registered capital to RMB 296,296 [2] - Kema Biotechnology, established in 2021, focuses on antibody design using generative AI models and aims to innovate antibody drug development [1][2] Group 2 - The global AI-driven drug development sector is rapidly growing, and there is a need for local Chinese companies to enhance their international competitiveness in this field [2] - The investment aligns with national strategies to promote digital development and the "AI+" initiative as outlined in the 15th Five-Year Plan [2]
华兰股份(301093.SZ)子公司灵擎数智拟投资科迈生物 进入AI创新药研发领域